Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists engineer self-destructing bacteria to kill cancer cells
Salmonella bacteria
Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.
In vivo method minimises damage to surrounding cells

Scientists at the University of California and the Massachusetts Institute have discovered a therapeutic approach to cancer that minimises damage to surrounding cells.

A study published in the journal Nature describes how researchers engineered self-destructing bacteria that release anti-cancer drugs within tumours.

“In synthetic biology, one goal of therapeutics is to target disease sites and minimise damage,” said lead author Jeff Hasty, professor of bioengineering and biology at UC San Diego.

In the study, Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.

Researchers say the use of bacteria to deliver cancer drugs in vivo is 'enticing' because conventional chemotherapy doesn't always reach the inner regions of a tumour.

Importantly, the researchers observed the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumour size.

“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a founder of the field of synthetic biology.

“Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronising cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com